Aims: The objectives of this study were to find out whether and to what extent Actinomyces neuii is pathogenic to humans in terms of causing invasive infections and to ascertain the most appropriate and effective antibiotic therapy against this bacterium. Material and method: This study was designed as a systematic review article. MEDLINE, Google Scholar, SCIndex, Cochrane database of published clinical trials - Central and Clinicaltrials.gov databases were systematically searched for primary case reports or case series describing invasive infection with Actinomyces neuii. Results: A literature search identified 23 studies that met the inclusion criteria, describing cases of patients with an invasive infection caused by Actinomyces neuii. It was found that A. neuii could cause endocarditis, endophthalmitis, osteomyelitis, pleural empyema, soft tissue abscesses, neonatal sepsis, ventriculoperitoneal shunt infections and periprosthetic tissue infections. The most prescribed antibiotics for the treatment of Actinomyces neuii infections were amoxicillin and vancomycin (n = 10; 12.3%), followed by penicillin (n =9; 11.1%), gentamicin (n = 6; 7.4%), ampicillin (n = 5; 6.2%) and ceftazidime (n = 4; 4.9%). Antibiotic treatment of infections caused by A. neuii was followed by clinical improvement or complete cure of all patients, with no recorded deaths. Conclusion: A. neuii has a relevant pathogenic potential to cause invasive infections of various organs and tissues, especially in immunocompromised individuals of any age. For the treatment of mild infections caused by this bacterium, the antibiotics of choice are penicillin or amoxicillin, while vancomycin should be used to treat severe infections caused by Actinomyces neuii.

Gout is a direct consequence of chronic hyperuricaemia, who 's prevalence is following sedentary lifestyle and improper diet dominated by foods rich in purines and non-alcoholic and alcoholic beverages with sweeteners. Since gout is associated with other serious comorbidities is essential that the treatment of this disease would be adequate. The results of numerous studies indicate that the worldwide therapy of gout is insufficient in most patients. There is no doubt that this assessment is true for the treatment of gout in the Republic of Serbia, and the reasons for such an assessment are numerous. The most important reason is related to the choice of drugs, because in Serbia they are only available xanthine oxidase inhibitors, which reduce the formation of uric acid, while drugs that increase the excretion of uric acid- Uricosuric drugs are not registered. Beside uricosurics, in Serbia is not registered neither colhicine, a drug that has a very important role in the prevention of adverse effects of antihyperuricaemia drugs in the first few weeks of treatment.